Rare Diseases
Page 2 • 12 itemsGain critical insights into global orphan drug development & rare disease market trends. Stay ahead in pharma R&D, investment, and regulatory strategy.
BioMarin Completes $3 Billion Acquisition of Amicus Therapeutics, Expands Rare Disease Portfolio with Galafold and Pompe Therapies
BioMarin's acquisition of Amicus adds globally approved Galafold for Fabry disease and POMBILITI/OPFOLDA combination for Pompe disease to its rare disease pipeline.
PMDA SAKIGAKE Designation: Review of Approved Drugs & Impact in Japan
This article reviews the PMDA SAKIGAKE Designation, highlighting approved drugs such as XYZ for cancer treatment and its significant impact on Japan's pharmaceutical landscape.
SAKIGAKE Designation Impact: Accelerating Rare Disease Drug Approvals in Japan
The SAKIGAKE Designation significantly speeds up the approval process for rare disease drugs in Japan, enhancing access to treatments like XYZ for patients with ABC condition.
Spinogenix Launches Phase 2b/3 CLARITY Trial of SPG601 for Fragile X Syndrome Treatment
Spinogenix initiates CLARITY Phase 2b/3 trial testing SPG601, a first-in-class oral therapy targeting BK channels for Fragile X Syndrome in male patients.
PMDA SAKIGAKE Designation: Transforming Innovative Drug Approvals in Japan
The PMDA SAKIGAKE Designation is revolutionizing the approval process for innovative drugs in Japan, ensuring faster access to essential treatments like XYZ for cancer patients.
PMDA SAKIGAKE Designation: Expedited Approval & Market Impact in Japan
Explore the significance of PMDA SAKIGAKE Designation in expediting approval processes and its impact on the market for drugs like XYZ in Japan.
Calluna Pharma Completes CAL101 Phase 2 Enrollment for Idiopathic Pulmonary Fibrosis Treatment
Calluna Pharma enrolls 161 patients in Phase 2 AURORA study of CAL101 for IPF treatment, six months ahead of schedule with topline data expected Q1 2027.
Argo Biopharma Begins Phase II Trials of BW-40202 siRNA Therapy for Rare Kidney Diseases
Argo Biopharma doses first patients in Phase II trials of BW-40202, an investigational siRNA therapy targeting complement factor B for PNH and IgAN treatment.
PMDA SAKIGAKE Designation: Expediting Innovative Drug Approvals in Japan
The PMDA SAKIGAKE Designation streamlines the approval process for innovative drugs, enhancing patient access to groundbreaking treatments in Japan.
NMPA Accelerated Approval: Transforming Innovative Drug Market Entry in China
NMPA's accelerated approval process is revolutionizing the market entry of innovative drugs, enhancing access to treatments like XYZ for cancer patients in China.
NMPA Accelerated Approval Pathway: Impact on China's Innovative Drug Market
The NMPA Accelerated Approval Pathway is transforming China's innovative drug market, expediting access to essential cancer therapies and fostering innovation.
PMDA SAKIGAKE Designation: Impact on Expedited Approvals & Rare Diseases
The PMDA SAKIGAKE Designation significantly impacts expedited drug approvals, particularly for rare diseases, improving access to treatments like XYZ drug.